586 results on '"Gordon, M. S."'
Search Results
102. Early evidence of tolerability and clinical activity from a phase I study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer
103. Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
104. Nanojets, Electrospray, and Ion Field Evaporation: Molecular Dynamics Simulations and Laboratory Experiments
105. First-in-human dose escalation safety and pharmacokinetic (PK) trial of a novel intravenous (IV) thrombospondin-1 (TSP-1) mimetic humanized monoclonal CovX Body (CVX-045) in patients (pts) with advanced solid tumors
106. Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): Final results from Southwest Oncology Group study 0317
107. A phase I study evaluating the effect of oxonic acid (Oxo) as a component of S-1 on the pharmacokinetics (PK) of 5-fluorouracil (5-FU)
108. Phase I study of the novel proteasome inhibitor NPI-0052 in patients with lymphoma and solid tumors
109. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics (PK) of 5-fluorouracil (5-FU)
110. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial
111. Recombinant IL-21 (rIL-21) in combination with sorafenib: Interim results from a phase 1/2 study in patients with metastatic renal cell cancer (mRCC)
112. Phase I studies of CBP501, a novel G2 checkpoint abrogator, alone and combined with cisplatin (CDDP) in advanced solid tumor patients (pts)
113. Single-event-upset and alpha-particle emission rate measurement techniques
114. Alpha-particle-induced upsets in advanced CMOS circuits and technology
115. New simulation methodology for effects of radiation in semiconductor chip structures
116. IR Photodissociation Spectroscopy and Theory of Au+(CO)n Complexes: Nonclassical Carbonyls in the Gas Phase
117. Evidence of self-correcting spiral flows in swimming boxfishes
118. Accurate ab initio potential energy curve of F2. III. The vibration rotation spectrum
119. Accurate ab initio potential energy curve of F2. II. Core-valence correlations, relativistic contributions, and long-range interactions
120. Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC)—SWOG S0317
121. Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors
122. Phase I study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 24-hour continuous infusion in patients with advanced solid tumors
123. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors
124. Ab initio molecular orbital study of the insertion of H2 into POSS compounds
125. Identification of a Vibrational Frequency Corresponding to H-atom Translocation in Hypericin¶
126. Synthesis of Hydroxy and Methoxy Perylene Quinones, Their Spectroscopic and Computational Characterization, and Their Antiviral Activity¶
127. Optical characterization of the Keck array polarimeter at the South Pole
128. Infrared Spectra and Ab Initio Calculations for the F-−(CH4)n (n = 1−8) Anion Clusters
129. Reply to “Comment on ‘Monotonically decreasing size distributions for one-dimensional Ga rows on Si(100)’ ”
130. Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T)
131. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer
132. Identification of predictive markers of clinical activity from a phase II trial of single agent pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer (OC)
133. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours
134. Hypericin and Its Perylene Quinone Analogues: Probing Structure, Dynamics, and Interactions with the Environment
135. Mechanical Pole Testing Using Partial Load Force for Application in Electric Utilities
136. A kinematic examination of wild sockeye salmon jumping up natural waterfalls
137. Monotonically decreasing size distributions for one-dimensional Ga rows on Si(100)
138. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma
139. Open-label, multicenter, phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma
140. Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status
141. Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): Safety, pharmacogenomics, pharmacokinetics, and tumor response
142. Phase I study of LErafAON-ETU, an easy-to-use formulation of liiposome entrapped c-raf antisense oligonucleotide, in advanced cancer patients
143. Phase I study of BMS-599626, an oral pan-HER tyrosine kinase inhibitor, in patients with advanced solid tumors
144. Hypericin and Its Perylene Quinone Analogs: Probing Structure, Dynamics, and Interactions with the Environment
145. Synthesis of Hydroxy and Methoxy Perylene Quinones, Their Spectroscopic and Computational Characterization, and Their Antiviral Activity¶
146. Ultrathin membrane masks for electron projection lithography
147. Low dose interferon-α2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A phase III study of the Eastern Cooperative Oncology Group (E2898)
148. Structures and Fragmentations of Small Silicon Oxide Clusters by ab Initio Calculations
149. Dynamics and Energetics of Animal Swimming and Flying: Introduction
150. Theoretical study of spin-orbit coupling constants for O2+ (A 2Π3/2,1/2u, v+=0–17 and a 4Π5/2,3/2,1/2,−1/2u, v+=0–25)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.